The present application describes novel hydantoin derivatives of formula (I): ##STR00001## or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R.sup.11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-.alpha. converting enzyme (TACE), aggrecanase, or a combination thereof.